Related Experiment Videos
Psoriasis improved by anthracene with near ultraviolet light
Journal of the American Academy of Dermatology
|September 1, 1979
Summary
Anthracene combined with UVA light therapy shows promise for treating psoriasis. This approach reduced plaque thickness and scaling in most patients, with some experiencing significant clearing.
Area of Science:
- Dermatology
- Photobiology
Background:
- Anthracene is known to inhibit epidermal deoxyribonucleic acid (DNA) synthesis and mitosis under near ultraviolet (UV) light (UVA).
- This inhibitory effect suggests a potential therapeutic application for conditions involving rapid epidermal proliferation, such as psoriasis.
Purpose of the Study:
- To investigate the efficacy of combining anthracene with UVA light in a preliminary clinical study for psoriasis treatment.
Main Methods:
- A small group of psoriasis patients were treated with anthracene and UVA light.
- Clinical assessments focused on changes in plaque thickness and scaling.
Main Results:
- Four out of five patients showed improvement, including reduced plaque thickness and scaling.
- Two of the four improved patients experienced complete or near-complete clearing of psoriasis lesions.
Conclusions:
- Anthracene in conjunction with UVA light demonstrates potential as a therapeutic option for managing psoriasis.
- Further clinical trials are warranted to confirm these preliminary findings.